MaxCyte outlines $30M–$32M 2026 revenue target as ExPERT DTx launch and SPL milestones drive outlook [Seeking Alpha]
MaxCyte, Inc. (MXCT)
Company Research
Source: Seeking Alpha
Maher Masoud, President, CEO & Executive Director, highlighted that 2025 was a challenging year but also one of "meaningful progress for MaxCyte." The company acquired SeQure DX, integrated the business, and launched the ExPERT DTx platform. Masoud stated, "We made meaningful changes Fresh Stock Ideas, Every Day Quick Insights The $4 million core revenue headwind from SPL customer program rationalization and a license termination, alongside biotechs' capital conservation, are the key factors contributing to lower guidance. MaxCyte is rightsizing spending, improving efficiency through restructuring, and launching new products like ExPERT DTx to engage earlier in drug discovery and support future growth. Management expects stabilization in the latter half of 2026 as industry dynamics improve, with renewed growth from non-SPL customers, SPL program ramp, and new product adoption. Recommended For You More Trending News
Show less
Read more
Impact Snapshot
Event Time:
MXCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MXCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MXCT alerts
High impacting MaxCyte, Inc. news events
Weekly update
A roundup of the hottest topics
MXCT
News
- MaxCyte (MXCT) had its price target lowered by Craig Hallum from $7.00 to $5.00. They now have a "buy" rating on the stock.MarketBeat
- MaxCyte, Inc. (MXCT) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- MaxCyte Inc (MXCT) Q4 2025 Earnings Call Highlights: Navigating Revenue Declines Amid Strategic ... [Yahoo! Finance]Yahoo! Finance
- MaxCyte (MXCT) Q4 2025 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- MaxCyte Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
MXCT
Earnings
- 3/24/26 - Miss
MXCT
Sec Filings
- 3/27/26 - Form 8-K
- 3/27/26 - Form SCHEDULE
- 3/25/26 - Form 10-K
- MXCT's page on the SEC website